or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.griseofulvingriseofulvin will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.haloperidolsolifenacin decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor.haloperidol increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.haloperidol and solifenacin both increase QTc interval. Use Caution/Monitor.henbanehenbane and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.histrelinsolifenacin and histrelin both increase QTc interval. Use Caution/Monitor.homatropinehomatropine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.huperzine Ahuperzine A increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.hydrocortisonehydrocortisone will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.hydroxyzinehydroxyzine and solifenacin both increase QTc interval. Use Caution/Monitor.hyoscyaminehyoscyamine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.hyoscyamine sprayhyoscyamine spray and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.iloperidonesolifenacin decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor.iloperidone increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.iloperidone increases levels of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.imipraminesolifenacin and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.solifenacin and imipramine both increase QTc interval. Use Caution/Monitor.indinavirindinavir will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ipratropiumipratropium and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.isoniazidisoniazid will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.istradefyllineistradefylline will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.lapatiniblapatinib will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.solifenacin and lapatinib both increase QTc interval. Use Caution/Monitor.lenacapavirlenacapavir will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates.letermovirletermovir increases levels of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.leuprolidesolifenacin and leuprolide both increase QTc interval. Use Caution/Monitor.lithiumlithium and solifenacin both increase QTc interval. Use Caution/Monitor.lofepraminesolifenacin and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.lofexidinesolifenacin and lofexidine both increase QTc interval. Use Caution/Monitor.loperamidesolifenacin and loperamide both increase QTc interval. Use Caution/Monitor.lorlatiniblorlatinib will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.loxapinesolifenacin decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.loxapine increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.loxapine inhaledloxapine inhaled increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.solifenacin decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.lumefantrinelumefantrine will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.maprotilinesolifenacin and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.marijuanamarijuana will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.meclizinemeclizine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.methscopolaminemethscopolamine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.methylprednisolonemethylprednisolone will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.metronidazolemetronidazole will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.miconazole vaginalmiconazole vaginal will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.mifepristonemifepristone, solifenacin. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.mifepristone will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.mirabegronmirabegron increases toxicity of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor patients for signs/symptoms of urinary retention.mirtazapinemirtazapine and solifenacin both increase QTc interval. Use Caution/Monitor.mitotanemitotane decreases levels of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.nafcillinnafcillin will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nelfinavirnelfinavir will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.neostigmineneostigmine increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.nevirapinenevirapine will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nifedipinenifedipine will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nilotinibnilotinib will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nortriptylinesolifenacin and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.solifenacin and nortriptyline both increase QTc interval. Use Caution/Monitor.octreotidesolifenacin and octreotide both increase QTc interval. Use Caution/Monitor.ofloxacinsolifenacin and ofloxacin both increase QTc interval. Use Caution/Monitor.olanzapinesolifenacin decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.olanzapine increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.olanzapine and solifenacin both increase QTc interval. Use Caution/Monitor.oliceridinesolifenacin increases toxicity of oliceridine by Other (see comment). Use Caution/Monitor. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics.onabotulinumtoxinAonabotulinumtoxinA and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.orphenadrinesolifenacin and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.osilodrostatosilodrostat and solifenacin both increase QTc interval. Use Caution/Monitor.osimertinibosimertinib and solifenacin both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.oxcarbazepineoxcarbazepine will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.oxybutyninoxybutynin and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.oxybutynin topicaloxybutynin topical and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.oxybutynin transdermaloxybutynin transdermal and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.ozanimodozanimod and solifenacin both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.paliperidonesolifenacin decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of paliperidone by pharmacodynamic antagonism. Use Caution/Monitor.paliperidone increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.pancuroniumpancuronium and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.pasireotidesolifenacin and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.pazopanibsolifenacin and pazopanib both increase QTc interval. Use Caution/Monitor.pentobarbitalpentobarbital will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.perphenazinesolifenacin decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of perphenazine by pharmacodynamic antagonism. Use Caution/Monitor.perphenazine increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.solifenacin and perphenazine both increase QTc interval. Use Caution/Monitor.phenobarbitalphenobarbital will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.phenytoinphenytoin will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.physostigminephysostigmine increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.pilocarpinepilocarpine increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.pimozidesolifenacin decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor.pimozide increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.posaconazoleposaconazole will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.prabotulinumtoxinAsolifenacin, prabotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.pralidoximepralidoxime and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.prednisoneprednisone will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.primaquineprimaquine and solifenacin both increase QTc interval. Use Caution/Monitor.primidoneprimidone will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.procainamidesolifenacin and procainamide both increase QTc interval. Use Caution/Monitor.prochlorperazinesolifenacin decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.solifenacin and prochlorperazine both decrease QTc interval. Use Caution/Monitor.promethazinesolifenacin decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.promethazine increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.solifenacin and promethazine both decrease QTc interval. Use Caution/Monitor.propanthelinepropantheline and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.protriptylinesolifenacin and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.solifenacin and protriptyline both increase QTc interval. Use Caution/Monitor.pyridostigminepyridostigmine increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.quetiapinesolifenacin decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of quetiapine by pharmacodynamic antagonism. Use Caution/Monitor.quetiapine increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.quinidinesolifenacin and quinidine both increase QTc interval. Use Caution/Monitor.quininesolifenacin and quinine both increase QTc interval. Use Caution/Monitor.quinupristin/dalfopristinquinupristin/dalfopristin will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ranolazinesolifenacin and ranolazine both increase QTc interval. Use Caution/Monitor.rapacuroniumrapacuronium and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.ribociclibribociclib will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.rifapentinerifapentine will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.rilpivirinesolifenacin and rilpivirine both increase QTc interval. Use Caution/Monitor.risperidonesolifenacin decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.risperidone increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.solifenacin and risperidone both increase QTc interval. Use Caution/Monitor.ritonavirritonavir will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.rivastigminesolifenacin decreases effects of rivastigmine by cholinergic effects/transmission. Use Caution/Monitor.rocuroniumrocuronium and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.romidepsinsolifenacin and romidepsin both increase QTc interval. Use Caution/Monitor.rucaparibrucaparib will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated.rufinamiderufinamide will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.scopolaminescopolamine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.secobarbitalsecobarbital will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.selpercatinibselpercatinib increases toxicity of solifenacin by QTc interval. Use Caution/Monitor.sertralinesertraline and solifenacin both increase QTc interval. Use Caution/Monitor.sorafenibsorafenib and solifenacin both increase QTc interval. Use Caution/Monitor.stiripentolstiripentol, solifenacin. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment.succinylcholinesuccinylcholine increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.sunitinibsolifenacin and sunitinib both increase QTc interval. Use Caution/Monitor.sunitinib and solifenacin both increase QTc interval. Use Caution/Monitor.tacrolimussolifenacin and tacrolimus both increase QTc interval. Use Caution/Monitor.tacrolimus and solifenacin both increase QTc interval. Use Caution/Monitor.tazemetostattazemetostat will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.tecovirimattecovirimat will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered.telavancinsolifenacin and telavancin both increase QTc interval. Use Caution/Monitor.thioridazinesolifenacin decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor.thioridazine increases